Literature DB >> 18257107

Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis.

Naseema Gangat1, Jacob J Strand, Terra L Lasho, Chin-Yang Li, Animesh Pardanani, Ayalew Tefferi.   

Abstract

Among 418 patients with polycythemia vera seen at our institution and in whom pruritus history was recorded, the presence of pruritus at diagnosis was documented in 131 (31%) and its absence in 287 (69%). Pruritus was less frequently reported by smokers (12% vs. 24%; P = 0.004) and diabetics (5% vs. 11%; P = 0.04). The presence of pruritus was associated with a lower rate of arterial thrombosis, both at diagnosis (8% vs. 17%; P = 0.01) and during follow-up (16% vs. 30%; P = 0.003). Multivariable analysis revealed that these associations were independent of other risk factors for thrombosis. High JAK2V617F allele burden clustered with pruritus (P = 0.002) but did not affect thrombosis rates. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18257107     DOI: 10.1002/ajh.21156

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.

Authors:  Michael R Grunwald; John M Burke; David J Kuter; Aaron T Gerds; Brady Stein; Mark A Walshauser; Shreekant Parasuraman; Philomena Colucci; Dilan Paranagama; Michael R Savona; Ruben Mesa
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-06-13

Review 2.  Polycythemia vera treatment algorithm 2018.

Authors:  Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-01-10       Impact factor: 11.037

Review 3.  A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

Authors:  Mary F F McMullin; Adam J Mead; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Claire N Harrison
Journal:  Br J Haematol       Date:  2018-11-13       Impact factor: 6.998

4.  Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP.

Authors:  C Le Gall-Ianotto; R Verdet; E Nowak; L Le Roux; A Gasse; A Fiedler; D Carlhant-Kowalski; P Marcorelles; L Misery; J C Ianotto
Journal:  Trials       Date:  2021-12-19       Impact factor: 2.279

5.  Delayed diagnosis of polycythaemia vera in an adult female with non-cirrhotic portal hypertension.

Authors:  Kenneth Tachi; Victor Ekem; Yvonne Dei-Adomakoh
Journal:  Ghana Med J       Date:  2022-03

Review 6.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

7.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Authors:  A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui
Journal:  Leukemia       Date:  2013-06-06       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.